$INDV News

Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)

Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

Indivior Q2 2026 Earnings Call: Complete Transcript

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108%

Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score

Indivior’s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV)

Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable

IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects